U.S. markets closed
  • S&P 500

    4,410.13
    +12.19 (+0.28%)
     
  • Dow 30

    34,364.50
    +99.13 (+0.29%)
     
  • Nasdaq

    13,855.13
    +86.21 (+0.63%)
     
  • Russell 2000

    2,033.51
    +45.59 (+2.29%)
     
  • Crude Oil

    84.06
    +0.75 (+0.90%)
     
  • Gold

    1,842.60
    +0.90 (+0.05%)
     
  • Silver

    23.99
    +0.19 (+0.78%)
     
  • EUR/USD

    1.1328
    -0.0027 (-0.24%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • GBP/USD

    1.3487
    -0.0059 (-0.43%)
     
  • USD/JPY

    114.0100
    +0.3550 (+0.31%)
     
  • BTC-USD

    36,702.61
    +451.55 (+1.25%)
     
  • CMC Crypto 200

    839.82
    +29.22 (+3.60%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,588.37
    +66.11 (+0.24%)
     

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CARA

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, Thomas Reilly, Chief Financial Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m. ET.

A webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com